| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8736470 | Autoimmunity Reviews | 2018 | 5 Pages |
Abstract
Considering what is currently published on the evidence here reviewed in the use of belimumab in clinical practice it is our understanding that belimumab it will be gradually incorporated in the armamentarium of treatment not necessarily on refractory patients. We believe that with the upcoming of the subcutaneous route in the near future should also help in widen the use of the belimumab to be considered in first line combination set ups.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Frederico Marcondes, Morton Scheinberg,